BioNTech SE filed an initial insider ownership report for Chief People Officer Kylie Jimenez. This Form 3 establishes her status as a reporting person under U.S. securities rules. The filing does not list any transactions or option exercises; it simply opens ongoing disclosure of future activity.
BioNTech SE is highlighting progress in its late-stage lung cancer portfolio with new clinical data to be presented at the European Lung Cancer Congress 2026 in Copenhagen. The company will showcase programs spanning immunomodulators, antibody-drug conjugates and mRNA-based cancer immunotherapies across multiple lung cancer settings.
Key updates include pumitamig, a PD-L1×VEGF-A bispecific immunomodulator with encouraging antitumor activity and survival outcomes in several Phase 1/2 trials in China, supporting ongoing global ROSETTA Lung-01 and Lung-02 trials. Gotistobart, a CTLA-4–targeting candidate, showed clinically meaningful antitumor activity and a 54% reduction in risk of death versus standard chemotherapy in stage 1 of the global Phase 3 PRESERVE-003 study in squamous NSCLC.
BioNTech also reported first clinical data for BNT326/YL202, a HER3-targeted ADC, in advanced NSCLC with antitumor activity and favorable safety, backing a combination trial with pumitamig. Overall, BioNTech is running 16 lung cancer trials, including four pivotal Phase 3 and five novel-novel combination studies.
BioNTech SE director Michael Motschmann has filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director and, in the data provided, does not report any insider buy, sell, gift, or option exercise transactions.
BioNTech SE Chief Operating Officer Sierk Poetting filed an initial ownership report showing a mix of direct, indirect and derivative interests in BioNTech ordinary shares. He holds options and phantom options over 18,416, 25,459, 8,838, 7,112 and 14,664 underlying ordinary shares with exercise prices including 113.9400, 185.2300 and 152.1000, expiring between 2031 and 2035. He also reports 11,047 performance share units tied to ordinary shares. In addition, he has 141,514 ordinary shares directly, 449,387 ordinary shares held through Tofino GmbH, where he is sole shareholder, and 1,638 ordinary shares held by immediate family, for which he disclaims beneficial ownership except for any pecuniary interest.
BioNTech SE director Helmut Wolfgang Jeggle reported his initial ownership of the company’s ordinary shares. The Form 3 shows he holds 332,316 ordinary shares directly and 656,951 ordinary shares indirectly as of March 18, 2026. The indirect shares are held by Salvia GmbH, where he serves as Chief Executive Officer and may be deemed to beneficially own the shares held by that entity.
BioNTech SE’s Chief Medical Officer, Ozlem Tureci, filed an initial Form 3 disclosing existing equity-based awards, rather than new share purchases or sales. The filing lists option grants over 18,416, 25,459 and 9,306 underlying ordinary shares, phantom options over 7,112 and 14,664 shares, and 11,633 performance share units.
Footnotes explain that these options and PSUs generally vest in equal annual installments over four years and become exercisable four years after grant, subject to performance-based conditions tied to BioNTech’s share price and, for PSUs, its performance relative to the Nasdaq Biotechnology Index.
BioNTech SE director Ulrich Wandschneider filed an initial statement of beneficial ownership. The filing reports indirect beneficial ownership of 1,927 ordinary shares.
The shares are held by beebusy Capital GmbH, where Wandschneider is the sole shareholder and may be deemed to beneficially own the shares. The filing does not report any recent share purchases or sales, only this existing position.
BioNTech SE Chief Commercial Officer Annemarie Hanekamp filed an initial Form 3 reporting derivative equity holdings. She holds an option over 8,838 ordinary shares and performance share units linked to 11,047 ordinary shares. Both awards vest in equal annual installments over four years, subject to performance conditions.
BioNTech SE filed a Form 144 notifying of a proposed sale of 150,000 American Depositary Shares on 03/11/2026 for an aggregate offering price of $12,583,500.00 on the Nasdaq Global Select market. The filing lists underlying sources including 95,000 shares from a stock option exercise and 55,000 shares from a private transaction.
BioNTech files its 2025 Form 20-F annual report, describing its mRNA-focused business, COVID-19 vaccine franchise and expanding oncology and antibody-drug conjugate pipelines. The company highlights extensive regulatory, clinical, manufacturing, competitive and intellectual property risks around developing and commercializing its product candidates.
Revenue is noted as heavily dependent on its COVID-19 vaccine, with demand expected to decrease, while future growth is tied to new oncology assets such as BNT327 and ADCs. BioNTech also discloses operational and geopolitical risks from global trials and supply chains, ESG and human-rights compliance obligations, and AI-related legal and reputational uncertainties. Ordinary shares outstanding were 239,970,804 as of March 3, 2025.